Anemia in chronic kidney disease: Treating the numbers, not the patients

JAMA Internal Medicine

Volumn 174, Issue 5, 2014, Pages 708-709

  Coyne, Daniel W ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD TRANSFUSION; CANCER GROWTH; CANCER RECURRENCE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; COMORBIDITY; DIABETIC PATIENT; DIALYSIS; DISEASE SEVERITY; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; MEDICARE; NOTE; OBSERVATIONAL STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE;

ANEMIA; BLOOD TRANSFUSION; HEMATINICS; HUMANS; IRON; PHYSICIAN'S PRACTICE PATTERNS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84899797045     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2013.13305     Document Type: Note

References (9)

1. US Renal Data System. USRDS 2008 Annual Data Report: Atlas of End Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2008.
2. Coyne DW. Use of epoetin in chronic renal failure. JAMA. 2007;297(15):1713-1716.
3. WinkelmayerWC,Mitani AA, Goldstein BA, BrookhartMA, Chertow GM. Trends in anemia care in older patients approaching end-stage renal disease in the United States (1995-2010) [published online March 3, 2014]. JAMA Intern Med. doi:10.1001/jamainternmed.2014.87.
4. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339(9):584-590.
5. Coyne DW. The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial. Kidney Int. 2012;82(2):235-241.
6. Singh AK, Szczech L, Tang KL, et al; CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085-2098.
7. Pfeffer MA, Burdmann EA, Chen CY, et al; TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361(21):2019-2032.
8. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for 2006 updates: hemodialysis adequacy, peritoneal dialysis adequacy and vascular access. Am J Kidney Dis. 2006;48(suppl 1):A1-A6, S1-S322.
9. National Kidney Foundation. KDOQI clinical practice guidelines for anemia of chronic kidney disease, 2000. Am J Kidney Dis. 2001;37 (suppl 1):S182-S238.